Drug Profile
Hib-DTP-hepatitis B vaccine - Heber Biotec/Center for Genetic Engineering and Biotechnology
Alternative Names: Heberpenta 4+1; Heberpenta-LLatest Information Update: 17 Dec 2013
Price :
$50
*
At a glance
- Originator Center for Genetic Engineering and Biotechnology
- Developer Center for Genetic Engineering and Biotechnology; Heber Biotec
- Class Bacterial vaccines; Conjugate vaccines; Haemophilus vaccines; Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Tetanus
Most Recent Events
- 01 Dec 2013 Launched for Diphtheria, Haemophilus infections, Pertussis, Tetanus and Hepatitis B (prevention in infants and children) in Argentina, Ecuador, Uruguay and Venezuela before December 2013 (IM)
- 01 Dec 2010 Launched for Diphtheria, Tetanus, Pertussis, Haemophilus infections and Hepatitis B (prevention in infants and children) in Cuba (IM; liquid premixed)
- 10 Nov 2009 Phase-II clinical trials in Diphtheria, Tetanus, Pertussis, Haemophilus infections and Hepatitis B (prevention in infants and children) in Cuba (IM; liquid premixed)